Immunomodulation with Methotrexate Improves Treatment Response to Pegloticase in Uncontrolled Gout-Reference-Cited by-同舟云学术

Immunomodulation with Methotrexate Improves Treatment Response to Pegloticase in Uncontrolled Gout

Published:2022 Issue:2 Volume:1 Page:42
ISSN:2635-1420
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Peterson Jeff,

Abstract

The combination of methotrexate and pegloticase not only improves response rate by nearly double but also reduces infusion reactions by nearly eightfold. This is significant as a major drawback of using pegloticase monotherapy was the significant infusion reactions that made many practitioners unwilling to use the medication in patients with severe gout who may not have responded to conventional therapies. Those patients now have a chance to live a normal life free from gout.

Funder

This article is published under the Creative Commons Attribution Non-commercial License.

Publisher

Touch Medical Media, Ltd.

Reference14 articles.

1. Golenbiewski J, Keenan RT. Moving the needle: Improving the care of the gout patient. Rheumatol Ther. 2019;6:179–93.

2. Loffler W, Fairbanks L. Refractory gout – Does it exist? Nucleosides Nucleotides Nucleic Acids. 2020:39:1410–23.

3. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims. J Rheumatol. 2004;31:1575–81.

4. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28:437–43.

5. Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: A randomised controlled trial. Lancet. 2018;392:1403–12.